and they work by taking out amyloid beta from the brain. Amyloid is part of what causes Alzheimer's disease. Now, what we're ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A new study has used powerful imaging to reveal a subset of Alzheimer's-associated proteins spreading particularly rapidly.

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...